- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Tony Berberabe, MPH | Authors
Long-Term Follow-Up Spotlights Ongoing Positive Outcomes With Selpercatinib in RET Fusion–Positive Cancers
July 02, 2022
Patients with RET fusion–positive solid tumors continued to experience benefit from treatment with selpercatinib, according to extended follow-up from the phase 1/2 LIBRETTO-001 basket study.
Pembrolizumab Plus Chemotherapy With or Without Bevacizumab Consistently Improves Survival in Advanced Cervical Cancer Subgroups
June 06, 2022
Results from the phase 3 KEYNOTE-826 trial show a significant survival benefit with pembrolizumab plus chemotherapy with or without bevacizumab in most patient subgroups with persistent, recurrent, or metastatic cervical cancer.
Exploratory Analysis Continues to Support Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer
June 05, 2022
Data on next line of therapy from the phase 3 Study 309/KEYNOTE-775 trial emphasized the benefit of lenvatinib plus pembrolizumab for advanced endometrial cancer.
Early Data Show Epcoritamab Induces Responses in High-Risk DLBCL in First Line
June 04, 2022
High response rates were noted in a phase 1/2 trial of the bispecific antibody epcoritamab to treat first-line, high-risk diffuse large B-cell lymphoma.
Infigratinib Appears Active, Tolerable in Upper Tract Urothelial Carcinoma
May 22, 2022
Patients with upper tract urothelial carcinoma may benefit from treatment with oral FGFR1-3 inhibitor infigratinib.
ZUMA-5 Data Indicate Response and Efficacy With Axi-Cel in Indolent Non-Hodgkin Lymphoma at 2-Year Follow-Up
April 25, 2022
The use of axicabtagene ciloleucel for relapse/refractory indolent non-Hodgkin lymphoma continued the duration of response during the follow-up of the phase 2 ZUMA-5 trial.
Sotigalimab Plus Pembrolizumab Demonstrates Favorable Safety Profile in Metastatic Melanoma
April 13, 2022
The combination of sotigalimab plus pembrolizumab was associated with a tolerable safety profile in patients with unresectable stage III or IV metastatic melanoma.
Type of Frontline Immunotherapy Does Not Affect Responses With Second-Line Cabozantinib in Advanced RCC
February 20, 2022
Treatment with cabozantinib in the second line yielded responses in patients with advanced renal cell carcinoma who received immunotherapy in the frontline, regardless of prior regimen.
Niraparib/Cabozantinib Yields Promising Preliminary Safety, Efficacy in mUC and RCC
February 19, 2022
Patients with previously treated metastatic urothelial carcinoma or renal cell carcinoma experienced promising benefit from treatment with niraparib and cabozantinib.
Regorafenib Plus Pembrolizumab Combo Misses PFS End Point, Shows Strong OS for MSS Colorectal Cancer
January 22, 2022
Although the combination of regorafenib and pembrolizumab failed to meet significance for progression-free survival, an improvement in overall survival and disease control were observed for patients with microsatellite stable colorectal cancer.